4.7 Article

AKAP12 ameliorates liver injury via targeting PI3K/AKT/PCSK6 pathway

Journal

REDOX BIOLOGY
Volume 53, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.redox.2022.102328

Keywords

AKAP12; PCSK6; Inflammatory factor; Macrophage infiltration; Liver injury

Funding

  1. Special Clinical Research Project of Shanghai Municipal Health Commission [202140147]
  2. Outstanding academic leaders plan of Shanghai [2018BR07]
  3. Shanghai Key Laboratory of Hepato-biliary Tumor Biology and Military Key Laboratory on Signal Transduction
  4. Key Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer (SMMU) , Ministry of Education

Ask authors/readers for more resources

This study demonstrates the protective role of AKAP12 in acute liver injury and chronic liver fibrosis, at least partially through inhibition of the PI3K/AKT/PCSK6 pathway. These findings provide a new potential treatment for liver injury and have important clinical implications.
A kinase anchor protein 12(AKAP12)is a scaffold protein that is critical for cell structure maintenance and signal transduction. However, the role of AKAP12 in liver injury remains unclear. Here, we attempt to explore the potential contribution of AKAP12 in liver injury and elucidate its underlying molecular mechanism. We found that AKAP12 deletion in acute liver injury (ALI) activates the PI3K/AKT phosphorylation signaling pathway, induces the increased expression of PCSK6 and its downstream inflammation-related genes, and prompts macrophages to produce a large number of inflammatory factors. And knockdown of PCSK6 by in vivo siRNA assay reversed in liver injury AKAP12 Delta hep mice, demonstrating that PCSK6 has an important role in ALI. Furthermore, we found that signal transducer and activator of transcription 3 (STAT3) and serine/threonine kinase Akt (AKT) were upregulated in AKAP12 Delta hep mice of chronic liver injury. To sum up, our study here demonstrates that AKAP12 has a protective role in ALI and chronic liver fibrosis, at least in part through inhibition of the PI3K/AKT/PCSK6 pathway. Our findings provide a new potential treatment for liver injury with important clinical implications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available